image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Our latest issue will be released in 5 days, don't miss out!

Somero

March 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • SOM
  • Price:
  • 430p
Having been sure footed for so long, Somero said it expected full year revenue to be slightly lower than expected at US$134m (guidance: US$138m). This is virtually unchanged on FY’21 but still 52% higher than ’20 and reflects some customer supply constraints, notably inconsistent availability of concrete, which Somero levels into a flat surface with its specialist kit.  North America bore the brunt with trading slightly down from FY'21’s record US$106.7m, while the much smaller Europe (+20%) and Australia (+40%) regions made good progress.  FinnCap has reduced pretax profit forecasts by 3.4% to US$44.6m and eps by 3.7 cents to 60.4 cents (49.9p). For FY’23 it reduced pretax profit by almost 7% to US$4.3m for eps of 55.9 cen ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author